Brokerages Set TransMedics Group, Inc. (NASDAQ:TMDX) Target Price at $122.70

TransMedics Group, Inc. (NASDAQ:TMDX) has been given a consensus rating of “Moderate Buy” by the eleven brokerages that are currently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $124.20.

A number of analysts have recently issued reports on TMDX shares. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, April 23rd. Piper Sandler reiterated an “overweight” rating and set a $105.00 target price (up previously from $90.00) on shares of TransMedics Group in a research note on Tuesday. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $104.00 price target on shares of TransMedics Group in a research note on Tuesday, March 11th.

TransMedics Group Stock Down 0.5 %

TMDX stock opened at $89.98 on Monday. TransMedics Group has a 1-year low of $55.00 and a 1-year high of $177.37. The business’s 50 day simple moving average is $76.02 and its 200 day simple moving average is $76.72. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The firm has a market capitalization of $3.04 billion, a PE ratio of 95.72 and a beta of 2.14.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TMDX. Braidwell LP bought a new stake in shares of TransMedics Group during the 4th quarter valued at approximately $57,493,000. Norges Bank bought a new stake in shares of TransMedics Group during the fourth quarter worth $22,861,000. Mackenzie Financial Corp increased its holdings in shares of TransMedics Group by 73.0% during the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock worth $51,635,000 after buying an additional 349,403 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of TransMedics Group by 1,565.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company’s stock valued at $16,820,000 after acquiring an additional 253,624 shares during the last quarter. Finally, Emerald Advisers LLC boosted its holdings in shares of TransMedics Group by 146.3% during the 4th quarter. Emerald Advisers LLC now owns 371,711 shares of the company’s stock valued at $23,176,000 after acquiring an additional 220,804 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.